Six-month interim report (Q2) 2015 for ALK
August 18, 2015 02:00 ET
|
ALK Abello
Copenhagen, 2015-08-18 08:00 CEST (GLOBE NEWSWIRE) --
Performance for the period (unaudited)
(Comparative figures for 2014 are shown in brackets / revenue growth is measured in local...
BioCryst Reports Second Quarter 2015 Financial Results
August 07, 2015 06:50 ET
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Aug. 7, 2015 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial results for the second quarter ended June 30, 2015.
"During the...
ALK’s partner for Japan reports positive Phase II/III trial results for Japanese Cedar SLIT-tablet
August 07, 2015 03:00 ET
|
ALK Abello
Copenhagen, 2015-08-07 09:00 CEST (GLOBE NEWSWIRE) --
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that its partner for Japan, Torii Pharmaceutical Co., Ltd. (TSE: 4551), has...
ALKs partner i Japan rapporterer positive resultater fra fase II/III-studie med tabletten mod japansk cedertræsallergi
August 07, 2015 03:00 ET
|
ALK Abello
København, 2015-08-07 09:00 CEST (GLOBE NEWSWIRE) --
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) meddelte i dag, at ALKs partner i Japan, Torii Pharmaceutical Co., Ltd. (TSE: 4551), har...
BioCryst Licenses Worldwide Rights to Commercialize RAPIVAB(R) Influenza Treatment to CSL Limited
June 17, 2015 06:50 ET
|
BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., June 17, 2015 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc., (Nasdaq:BCRX) and CSL Limited (ASX:CSL) (USOTC:CSLLY) – BioCryst Pharmaceuticals, Inc., a...
H1N1 Vaccines - Global Strategic Business Report 2015
June 11, 2015 06:41 ET
|
Research and Markets
Dublin, June 11, 2015 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/lnxxj6/h1n1_vaccines) has announced the addition of the "H1N1 Vaccines -...
ALK’s partner, MSD, publishes Phase II data on house dust mite SLIT-tablet in leading allergy journal journal
June 10, 2015 07:10 ET
|
ALK Abello
Copenhagen, 2015-06-10 13:10 CEST (GLOBE NEWSWIRE) --
Results show significant improvement of nose and eye symptoms
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that its...
ALK announces top-line results from its partner MSD’s North American Phase III trial of house dust mite SLIT-tablet
June 04, 2015 01:36 ET
|
ALK Abello
Copenhagen, 2015-06-04 07:36 CEST (GLOBE NEWSWIRE) --
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): Trial meets primary endpoint by significantly improving total combined allergic rhinitis...
ALK offentliggør hovedresultater fra partneren MSDs nordamerikanske fase III-studie med tabletvaccinen mod husstøvmideallergi
June 04, 2015 01:36 ET
|
ALK Abello
København, 2015-06-04 07:36 CEST (GLOBE NEWSWIRE) --
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): Studiet når sit primære mål og viser en signifikant forbedring af den totale kombinerede...
CORRECTION: ALK to present at two upcoming 2015 Investor Conferences
May 27, 2015 09:39 ET
|
ALK Abello
Copenhagen, 2015-05-27 15:39 CEST (GLOBE NEWSWIRE) --
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that the Company will present at the Jefferies 2015 Global Healthcare...